NCT01532635 · OUTCOME
Chimerism Assessment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- 1 year
What was measured
To assess chimerism to ascertain whether one donor is emerging as dominant at regular intervals beginning at the time of engraftment.
Groups in this outcome
Allogeneic HSCT Using Two Related Donors
CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2. TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28.
| Group | Source count |
|---|---|
| Allogeneic HSCT Using Two Related Donors | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- To assess chimerism to ascertain whether one donor is emerging as dominant at regular intervals beginning at the time of engraftment.
- groups
- description
- CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2. TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28.
- id
- OG000
- title
- Allogeneic HSCT Using Two Related Donors
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Chimerism Assessment
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle